<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946123</url>
  </required_header>
  <id_info>
    <org_study_id>L-carnitine Hyperthyroidism</org_study_id>
    <nct_id>NCT04946123</nct_id>
  </id_info>
  <brief_title>Hyperthyroidism: Methimazole Plus L-carnitine and Selenium</brief_title>
  <official_title>Association of Methimazole With L-carnitine and Selenium in Patients With Hyperthyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lo.Li.Pharma s.r.l</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lo.Li.Pharma s.r.l</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate the benefits of methimazole treatment in patients with&#xD;
      hyperthyroidism, associated with supplementation of L-carnitine and Selenium.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperthyroidism symptoms</measure>
    <time_frame>Change from baseline QoL at 6 months of supplementation</time_frame>
    <description>Improvement of the patients' quality of life through questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyperthyroidism symptoms</measure>
    <time_frame>Change from 6-months supplementation QoL at 12 months of intervention (end of study)</time_frame>
    <description>Improvement of the patients' quality of life through questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TRAb</measure>
    <time_frame>Four time points: baseline; after 3 months of supplementation; after 6 months of supplementation; end of the study (12 months)</time_frame>
    <description>Change in serum TRAb (TSH receptor antibodies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSH</measure>
    <time_frame>Four time points: baseline; after 3 months of supplementation; after 6 months of supplementation; end of the study (12 months)</time_frame>
    <description>Change in serum TSH (Thyroid stimulating hormone)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hyperthyroidism</condition>
  <arm_group>
    <arm_group_label>methimazole (control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with hyperthyroidism under methimazole treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methimazole+L-carnitine+selenium (intervention)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hyperthyroidism under methimazole treatment + supplementation with L-carnitine and Selenium</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-carnitine+Selenium</intervention_name>
    <description>Supplementation with L-carnitine and Selenium</description>
    <arm_group_label>methimazole+L-carnitine+selenium (intervention)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of hyperthyroidism requiring therapy with methimazole&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Drug and alcohol abuse;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Medically uncontrolled psychiatric conditions;&#xD;
&#xD;
          -  Interfering therapies (lithium, interferone, TKI, amiodarone)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Loredana Pagano, MD</last_name>
    <phone>+39 339 6918551</phone>
    <email>lpagano@cittadellasalute.to.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Citt√† della scienza e degli studi di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loredana Pagano, Dr</last_name>
      <phone>+39 3396918551</phone>
      <email>lpagano@cittadellasalute.to.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

